Senolytics decrease senescent cel…etic kidney disease.
🔬 Peer-reviewed
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.
LaTonya J Hickson, Larissa G P Langhi Prata, Shane A Bobart, Tamara K Evans, Nino Giorgadze, Shahrukh K Hashmi + 27 more
EBioMedicine · 2019
Findings
In a small 9-person trial, people took Dasatinib and Quercetin for 3 days. Within 11 days, researchers found fewer senescent cells (aging cells that trigger inflammation) in skin and fat tissue, plus lower levels of inflammatory markers in blood like IL-6 and MMP-9. This is the first human study directly showing senolytics can reduce senescent cells, though the sample size is tiny and long-term effects are unknown.
Design
Review
Evidence
Moderate
Journal
EBioMedicine